Show simple item record

dc.contributor.authorde Boer, SM
dc.contributor.authorWortman, BG
dc.contributor.authorBosse, T
dc.contributor.authorPowell, ME
dc.contributor.authorSingh, N
dc.contributor.authorHollema, H
dc.contributor.authorWilson, G
dc.contributor.authorChowdhury, MN
dc.contributor.authorMileshkin, L
dc.contributor.authorPyman, J
dc.contributor.authorKatsaros, D
dc.contributor.authorCarinelli, S
dc.contributor.authorFyles, A
dc.contributor.authorMcLachlin, CM
dc.contributor.authorHaie-Meder, C
dc.contributor.authorDuvillard, P
dc.contributor.authorNout, RA
dc.contributor.authorVerhoeven-Adema, KW
dc.contributor.authorPutter, H
dc.contributor.authorCreutzberg, CL
dc.contributor.authorSmit, VTHBM
dc.date.accessioned2020-12-09T23:23:29Z
dc.date.available2020-12-09T23:23:29Z
dc.date.issued2018-02-01
dc.identifierpii: S0923-7534(19)35063-X
dc.identifier.citationde Boer, S. M., Wortman, B. G., Bosse, T., Powell, M. E., Singh, N., Hollema, H., Wilson, G., Chowdhury, M. N., Mileshkin, L., Pyman, J., Katsaros, D., Carinelli, S., Fyles, A., McLachlin, C. M., Haie-Meder, C., Duvillard, P., Nout, R. A., Verhoeven-Adema, K. W., Putter, H. ,... Smit, V. T. H. B. M. (2018). Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. ANNALS OF ONCOLOGY, 29 (2), pp.424-430. https://doi.org/10.1093/annonc/mdx753.
dc.identifier.issn0923-7534
dc.identifier.urihttp://hdl.handle.net/11343/253209
dc.description.abstractBackground: In the PORTEC-3 trial, women with high-risk endometrial cancer (HR-EC) were randomised to receive pelvic radiotherapy (RT) with or without concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2). Pathology review was required before patient enrolment. The aim of this analysis was to evaluate the role of central pathology review before randomisation. Patients and methods: A total of 1295 cases underwent pathology review to confirm HR-EC in the Netherlands (n = 395) and the UK (n = 900), and for 1226/1295 (95%) matching review and original reports were available. In total, 329 of these patients were enrolled in the PORTEC-3 trial: 145 in the Netherlands and 184 in the UK, comprising 48% of the total PORTEC-3 cohort of 686 participants. Areas of discrepancies were evaluated, and inter-observer agreement between original and review opinion was evaluated by calculating the kappa value (κ). Results: In the 1226 pathology reviews, 6356 selected items were evaluable for both original and review pathology. In 43% of cases at least one pathology item changed after review. For 102 patients (8%), this discrepancy led to ineligibility for the PORTEC-3 trial, most frequently due to differences in the assessment of histological type (34%), endocervical stromal involvement (27%) and histological grade (19%). Lowest inter-observer agreement was found for histological type (κ = 0.72), lymph-vascular space invasion (κ = 0.72) and histological grade (κ = 0.70). Conclusion: Central pathology review by expert gynaeco-pathologists changed histological type, grade or other items in 43% of women with HR-EC, leading to ineligibility for the PORTEC-3 trial in 8%. Upfront pathology review is essential to ensure enrolment of the target trial-population, and to avoid over- or undertreatment, especially when treatment modalities with substantial toxicity are involved. This study is registered with ISRCTN (ISRCTN14387080, www.controlled-trials.com) and with ClinicalTrials.gov (NCT00411138).
dc.languageEnglish
dc.publisherOXFORD UNIV PRESS
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleClinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
dc.typeJournal Article
dc.identifier.doi10.1093/annonc/mdx753
melbourne.affiliation.departmentMedical Education
melbourne.source.titleAnnals of Oncology
melbourne.source.volume29
melbourne.source.issue2
melbourne.source.pages424-430
dc.rights.licenseCC BY
melbourne.elementsid1308296
melbourne.contributor.authorMileshkin, Linda
melbourne.contributor.authorPyman, Jan
dc.identifier.eissn1569-8041
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record